Hypertension, Essential Clinical Trial
Official title:
A Randomized, Double-Blind, Parallel, Multi-Center, Phase 2 Clinical Trial to Evaluate the Efficacy and Safety of AD-209 in Patients With Essential Hypertension
The purpose of this study is to evaluate the efficacy and safety of AD-209
Condition or disease : hypertension Intervention/treatment Drug : AD-209 Drug : AD-209-1A Drug : AD-209-1B Drug : AD-209-1C Drug : AD-209 Placebo Drug : AD-209-1 Placebo Phase : Phase 2 ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT06448962 -
Phase 3 Study to Evaluate the Efficacy and Safety of Co-administrated AD-2021 and AD-2022
|
Phase 3 | |
| Completed |
NCT01227603 -
Single Dose Bioequivalence Study Comparing Nifedipine/Candesartan FDC (Fixed Dose Combination) With Loose Combination of Nifedipine GITS (Gastro-intestinal Therapeutic System) Plus Candesartan and Single Components Under Fasting Conditions
|
Phase 1 | |
| Completed |
NCT03258489 -
Effects of TENS and IES on the Autonomous Balance of Normotens Volunteers and Hypertensive Patients
|
N/A | |
| Terminated |
NCT02245230 -
Cardiovascular Effects of Angiotensin (1-7) in Essential Hypertension
|
Phase 1 | |
| Completed |
NCT02466490 -
Efficacy and Safety of Fimasartan Alone or Combined With HCTZ in Mexican Patients With Essential Hypertension
|
Phase 3 | |
| Completed |
NCT01303783 -
Study of Nifedipine GITS and Candesartan Combination Compared to Monotherapy in Patients With Essential Hypertension
|
Phase 2 | |
| Completed |
NCT01350609 -
Pivotal Bioequivalence FDC Nifedipine / Candesartan vs. Loose Combination of Single Components, Fed
|
Phase 1 | |
| Not yet recruiting |
NCT04332562 -
The Association Between Serum β-hydroxybutyrate and Levels of Systemic Hypertension
|
N/A |